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Metastatic Follicular Carcinoma of the Thyroid: 
Reappearance of Radioiodine Uptake
Wim J.G. Oyen, Aart H. Mudde, Wim J.M. van den Broek and Frans H.M, Corstens
Department of Nuclear Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; and Department of Internal 
Medicine, Slingeland Ziekenhuis, Doetinchem, The Netherlands
Dedifferentiation of well-differentiated thyroid carcinoma is a 
well-known phenomenon that may lead to the disappearance of 
radioiodine uptake in tumors and the inability to treat patients 
with radioiodine. We report a patient in whom the 1311 uptake 
progressively diminished to such low levels after a cumulative 
dose of 31.5 GBq that further1311 administration was considered 
nonbeneficial. Thereafter, metastases In the lungs and skeleton 
progressed. Because of the absence of any other therapeutic 
options, nearly 2 yr later we decided to reperform 1311 measure­
ments and scanning under hypothyroid conditions. All known 
metastatic lesions this time showed intense 1311 uptake, more 
than 10-fold the previously measured values. High-dose 1311 
treatment was restarted.
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IN ^Ietastatic thyroid carcinoma is one of the major in­
dications for diagnostic studies and subsequent treatment 
with radioiodine (7). When metastatic lesions show suffi­
cient radioiodine uptake, treatment with such radiophar­
maceutical has been shown to significantly prolong life and 
in a number of patients to even achieve a cure (2,5). How­
ever, in the course of multiple-dose treatment regimens, 
selection of noniodine accumulating tumor cells and/or cel­
lular dedifferentiation may cause a decline of iodine uptake 
in tumor cells resulting in a detriment of radioiodine treat­
ment effectiveness (2). This may result in such low uptake 
values that effective treatment is no longer possible (2). We 
report a patient in whom 131I treatment for metastatic fol­
licular thyroid carcinoma was discontinued for this reason. 
However, in the course of her disease, progressive metas­
tases without any other therapeutic option made us decide 
to re-evaluate radioiodine uptake of the metastatic tumors.
CASE REPORT
A  64-yr-old female presented with a growing nodule in a 
pre-existing multinodular goiter which had been visualized
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as a cold area of the thyroid on a [99mTc]pertechnetate 
scan. Cytological examination of fine-needle aspirate did 
not rule out malignancy. Therefore, partial and subsequent 
total thyroidectomies were performed. Histological exam­
ination showed follicular adenocarcinoma of the thyroid 
invading blood vessels and surrounding tissue. The patient 
was kept off thyreomimetic medication for 1 mo to achieve 
high thyroid-stimulating hormone (TSH) levels.
The patient was then given an i.v. injection of 37 MBq 
sodium 131I. Radioiodine distribution and retention was 
evaluated 2 and 7 days after injection using a shadow- 
shield, whole-body counter and gamma camera imaging 
equipped with a high-energy, parallel-hole collimator. The 
131I study revealed a large area of 131I uptake in the neck. 
Because of these findings, the patient was treated with 5.5 
GBq 131I. Scintigraphic images obtained after the therapeu­
tic dose revealed two pulmonary metastases along with the 
known thyroid remnants in the neck. Thyreomimetic treat­
ment was started at a dosage to ensure suppressed TSH 
levels. Five, 10 and 15 mo after thyroidectomy, the patient 
was re-evaluated after temporary discontinuation of 
thyreomimetic medication to ensure elevated TSH levels. 
These studies showed progressive tumor growth in the 
neck and cervical spine and progressive metastases in the 
chest. Since sufficient 131I uptake for a partial therapeutic 
effect was noted, treatment was continued with 5.5,5.5 and 
7.5 GBq, respectively (Table 1) for several months. Over 
time, 131I uptake in the lesions progressively diminished.
Whole-body imaging after i.v. injection of 75 MBq 201 Tl- 
chloride [to assess noniodine-accumulating tumor (4)] con­
sistently showed uptake in the neck and lungs. Rapid 
growth of the tumor in the neck necessitated surgical de- 
bulking of the tumor 16 mo after thyroidectomy. Complete 
resection was impossible since the trachea and recurrent 
nerves were encapsulated by the tumor. Twenty months 
after thyroidectomy, there was still 131I uptake in the neck 
and lungs. A  new lesion in the left femur was visualized. 
The patient was again treated with 7.5 GBq 131I. The thy- 
roglobulin level, a serum marker for differentiated thyroid 
carcinoma (5), was now measurable due to the disappear­
ance of auto-antibodies against thyroglobulin, which was 
clearly elevated (200 pmole/liter, normal value <10 pmole/ 
liter). Evaluation 5 mo later (25 mo post-thyroidectomy) 
showed only minimal 131I retention in the large neck tumor.
Reappearance of Radioiodine Uptake • Oyen et al 613
TABLE 1
Radioiodine Examinations under Hypothyroid Conditions, Laboratory Findings, Subsequent Therapeutic 131l Dose and
Scintigraphic Findings
Month*
1
Day
p.i.
0
2
7
WBR+
100
16.3
8.8
Uptake (%)
Neck
5.2 
9.5 
3.7
Chest
n.e.
TSH*
(mE/l)
39.0
TG §
(pmole)
a. a.
I*
(pinole)
0.15
Therapeutic 
dose (GBq)
5.5
131 scintigraphy
Activity in neck ( 7 x 4  cm) 
and two spots in lungs
0
2
7
100
9.5
2.5
4.2
2.9
0.7
<0.5
< 0.1
31.6 a.a. 0.05 5.5 Activity in neck and 
multiple spots in lungs 
(progression)
10
15
20
0
2
7
0
0
2
100
3.4
1.0
100
4.5
0.7
100
2.8
0,5
3,3
0.6
0.2
3.3
0.7
0.1
2.9
0.4
0.1
<0.5
<0.1
<0.5
< 0.1
<0.5
<0.1
32.1
23.4
31.5
a .a
a.a.
200
0.03
0.08
0.05
5.5
7.5
7.5
Activity in neck and 
multiple spots in lungs 
(strong progression)
Activity in neck and 
several spots In lungs 
(regression of 
pulmonary lesions)
Vague activity in neck and 
several spots in lungs 
(stable); new lesion left 
femur
25
45
0
2
0
100
/
5.4
1.5
100
52.0
24.7
2.0
0.5
0.1
4.5 
4.2
2.6
<0.5
<0.1
18.9
8.9
33.5
32.0
194
209
0.02
0.03
none
7,5
Vague activity in neck; no 
visualization of 
métastasés in skeleton 
and lungs.
Increased activity in neck, 
both lungs and skeleton 
(spine, both femora, 
orbita, both humeri)
* Months after total thyroidectomy.
^Whole-body retention.
thyro id  stimulating hormone (normal values 0 .4 -4 .0  mE/l).
^Thyroglobulin normal value off thyreomimetics <10 pmole/liter); a.a. -  not evaluable due to too high auto-antibody levels against thyroglobulin, 
^Total plasma iodine level (normal values In hypothyroid phase <0.15 /xmole/liter; in case of excess iodine intake, such as after Injection of 
radiographic contrast agents higher than 1 mole/liter). Measurements according to the method reported by Foss et a I. (9).
**n.e. =  not evaluable due to high uptake in the neck.
Thyroglobulin remained at the same high level. Iodine con­
tamination as the cause for low 131I uptake was excluded 
(Table 1). Thallium-201 scanning also revealed uptake in 
left supraclavicular lymph nodes and stable, diffuse pulmo­
nary uptake. The lack of sufficient iodine uptake resulted in 
discontinuing 131I treatment.
External beam irradiation on the neck and cervical spine 
(27 x 2 Gy, 6 to 10 MeV photons) augmented with a 
weekly low dose adriamycin infusion 10 mg/m2 for 6 wk) 
resulted in a stable local condition and amelioration of the 
radicular syndrome of the left arm. In the following year, 
the patient was repeatedly admitted for complications of 
newly developed skeletal métastasés, such as fractures of 
both femora (osteosynthesis and single dose external beam 
irradiation (8 Gy), fracture of the right humerus (single 
dose external beam irradiation 8 Gy) and paresis of the
hypoglossal nerve. Rapid progression of especially the 
skeletal métastasés, and to a lesser degree the pulmonaiy 
métastasés, as well as the deterioration of the patient’s 
clinical condition made us re-evaluate the patient for 131I 
uptake in the tumor and métastasés 45 mo after thyroidec­
tomy in a hypothyroid situation. Surprisingly, whole-body 
retention 2 days after 131I injection was 52%, and 24.7% 
after 7 days, meaning a 10-fold and 15-fold increase as 
compared to the previous examination. This increased ra­
dioiodine retention was not caused by impaired renal func­
tion (kreatinin level 49 /¿mole/liter; normal range 45-90 
/¿mole/liter).
As shown in Table 1, tumor uptake in the neck and chest 
area showed significantly higher uptake than in previous 
examinations. In contrast, the thyroglobulin level was sim­
ilar to previous measurements (209 pmole/liter). Scinti-
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FIGURE 1. Anterior and posterior whole-body images 7 days 
after i.v. injection of 7.5 GBq 1311. There is extensive metastatic 
disease in the right orbital region, neck, chest, pelvis, spine and 
upper arms and legs.
graphic imaging revealed significant 131I uptake in the tu-
for delayed radioiodine excretion, was ruled out. Iodine 
contamination (e.g., due to intravenous radiographic con­
trast agents) was excluded as a cause for the previously 
low 131I uptake. One can hypothesize that progressive mé­
tastasés and massive tumor growth of the differentiated 
tumor cells occurred, while the anaplastic, noniodine con­
centrating cells did not spread. This is not likely to be the 
sole explanation of the findings in this patient, since it is 
well known that anaplastic thyroid carcinoma is much 
more aggressive than differentiated carcinoma. A second 
explanation may be that carcinoma cells with marginal 
radioiodine uptake differentiate at some stage during the 
course of the disease, so that with progressive tumor 
growth the 131I uptake increases. This last option is sup­
ported by repeat CT of the neck area, which indicated 
stable disease after the last course of external beam radio­
therapy, and by the more or less stable condition of the 
chest abnormalities over the last 2 yr.
In conclusion, disappearance of 131I uptake even just 
once does not necessarily mean it will be permanent. 
Therefore, when a progressive metastasis is observed, 131I
lesions and to decide whether further high dose 131I treat­
ment could be beneficial.
mor in the neck and cervical spine and a large number of studies can be reconsidered to assess l31I uptake in the
skeletal and pulmonary metastases (Fig. 1). This was rea­
son to resume treatment with 131I at a dose of 7,5 GBq.
Unfortunately, within 3 mo, the patient developed paraple­
gia due to spine metastasis and was confined to bed. Her REFERENCES
medical condition deteriorated very rapidly and she died L Blahd WH Treatment of malignant ,hyroki disease. Semin Nud Med 1979. 
within 2 wk. This short time span prevented assessment of 
any response to therapy.
DISCUSSION
With time, decreasing uptake of radioiodine in meta­
static differentiated thyroid carcinoma is a well-known 
phenomenon in the course of the disease. It may be in­
duced or accelerated by 131I treatment (2,6-8). Therefore, 
follow-up studies with radioiodine are often discontinued 
once 131I uptake has become so low that even under severe 
hypothyroid conditions no beneficial effects can be ex­
pected. In those conditions, palliative external beam irra­
diation is the only therapeutic option, which is known to be 
partially effective in anaplastic carcinoma (2). Our case 
indicates, however, that progressive metastases may re­
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uptake is difficult. Impaired renal function, a known cause
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